Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB08 in advanced solid neoplasms
NCT03006029Phase 1Completed
- Sponsor
- TheraMAB
- Start
- Feb 2017
- Primary completion
- May 2019
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of theralizumab in solid tumor, sponsored by TheraMAB. Primary endpoint: Dose-limiting toxicity at 2 weeks. Started Feb 2017; status: completed.
02
Drugs
theralizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03006029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006029.